ArticleAnnals of neurosciences2020
Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia.
Article in Annals of neurosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Linking Metabolic Disorders and Immune System Phenomena in Schizophrenia: The Role of Adipose Tissue and Inflammation.Biomedicines · 2025Review
- Effect of Electroconvulsive Therapy (ECT) on IL-1β, IP-10, IL-17, TNFα, IL-10 and Soluble IL-2 Receptor in Treatment-Resistant Schizophrenia (TRS) Patients-A Preliminary Study.Journal of clinical medicine · 2025Article
- Molecular and Functional Analysis of TLR 1, 2 and 6 in Peripheral Blood Monocytes of Patients with Schizophrenia: A Pilot Study.International journal of molecular sciences · 2025Article
- The Ketogenic Diet: An Anti-Inflammatory Treatment for Schizophrenia?Journal of inflammation research · 2025Review
- Hematological and biochemical markers and cytokine levels in hospitalized psychiatric patients with COVID-19.Frontiers in immunology · 2025Article
- Elevated serum IL-17 A and CCL20 levels as potential biomarkers in major psychotic disorders: a case-control study.BMC psychiatry · 2024Article
- Integrated Network Pharmacology and Molecular Docking to Explore the Mechanisms of Ningshen Wendan Decoction in the Treatment of Schizophrenia.Alpha psychiatry · 2024Article
- Cytokine expression profiles in children and adolescents with tic disorders.Scientific reports · 2024Article
- Microglia and Microbiome-Gut-Brain Axis.Advances in neurobiology · 2024Review
- Possible involvement of Interleukin-17A in the deterioration of prepulse inhibition on acoustic startle response in mice.Neuropsychopharmacology reports · 2023Article
- Schizophrenia Etiological Factors and Their Correlation with the Imbalance of the Immune System: An Update.Galen medical journal · 2023Review
- Dysregulation of Synaptic Plasticity Markers in Schizophrenia.Indian journal of clinical biochemistry : IJCB · 2023Review
- Network Association of Biochemical and Inflammatory Abnormalities With Psychiatric Symptoms in First-Episode Schizophrenia Patients.Frontiers in psychiatry · 2022Article
- Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study.Schizophrenia bulletin open · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlteration in cytokine levels are known to be involved in the pathogenesis of schizophrenia.
objectivesTo estimate the serum levels of interleukin-17 (IL-17) and interleukin-10 (IL-10) and their association with disease progression in schizophrenia.
methodsA total of 67 schizophrenia cases were enrolled in the present study. IL-17 and IL-10 were estimated by enzyme-linked immunosorbent assay. Positive and Negative Syndrome Scale (PANSS) was used to evaluate disease severity.
resultsIL-17 was positively correlated with positive symptom score (
conclusionIL-17 and IL-10 are associated with disease severity in schizophrenia but are not good markers for predicting the disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.